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Myotonic dystrophy (DM)—the most common form of muscular dystrophy in adults, affecting 1/8,000 individ-
uals—is a dominantly inherited disorder with a peculiar and rare pattern of multisystemic clinical features affecting
skeletal muscle, the heart, the eye, and the endocrine system. Two genetic loci have been associated with the DM
phenotype: DM1, on chromosome 19, and DM2, on chromosome 3. In 1992, the mutation responsible for DM1
was identiﬁed as a CTG expansion located in the 3′ untranslated region of the dystrophia myotonica-protein kinase
gene (DMPK). How this untranslated CTG expansion causes myotonic dystrophy type 1(DM1) has been contro-
versial. The recent discovery that myotonic dystrophy type 2 (DM2) is caused by an untranslated CCTG expansion,
along with other discoveries on DM1 pathogenesis, indicate that the clinical features common to both diseases are
caused by a gain-of-function RNA mechanism in which the CUG and CCUG repeats alter cellular function, including
alternative splicing of various genes. We discuss the pathogenic mechanisms that have been proposed for the
myotonic dystrophies, the clinical and molecular features of DM1 and DM2, and the characterization of murine
and cell-culture models that have been generated to better understand these diseases.
Introduction
Steinert (1909) and Batten and Gibb (1909) identiﬁed
myotonic dystrophy (DM [MIM 160900 and MIM
602668]) as a multisystemic disorder that is now rec-
ognized as one of the most common forms of muscular
dystrophy in adults. In addition to muscular dystrophy
and myotonia (involuntary persistence of muscle con-
traction), DM causes a consistent constellation of seem-
ingly unrelated and rare clinical features, including: car-
diac conduction defects, posterior subcapsular iridescent
cataracts, and a peculiar and speciﬁc set of endocrine
changes (Harper 2001). The 90 years between the iden-
tiﬁcation of myotonic dystrophy as a clinical disorder
and the identiﬁcation of the ﬁrst gene were important
for the development of a detailed description of the clin-
ical features, inheritance, and epidemiology of myotonic
dystrophy. Clinical neurologists and geneticists identiﬁed
non-Mendelian features of myotonic dystrophy type 1
(DM1) inheritance, including variable penetrance, an-
ticipation (a tendency for the disease to worsen in sub-
sequent generations), and a maternal transmission bias
for congenital forms (Harper 2001), all of which pre-
ceded the identiﬁcation of the CTG expansion respon-
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sible for DM1. The genetic cause of DM1 was identiﬁed
in 1992 as a (CTG)n repeat in the 3′-UTR of a protein
kinase gene (Brook et al. 1992; Buxton et al. 1992; Fu
et al. 1992; Harley et al. 1992; Mahadevan et al. 1992).
In 1995, several reports described families with dom-
inantly inherited multisystemic myotonic disorders that
were genetically distinct from DM1 (Ricker et al. 1994;
Rowland 1994; Thornton et al. 1994). Ricker and col-
leagues (1994) most thoroughly evaluated this new dis-
order and showed that the genetic cause in these families
was distinct from the known causes of myotonia con-
genita, paramyotonia, and DM1, demonstrating the ex-
istence of a novel genetic disorder. Because affected fam-
ily members often came to medical attention because of
pelvic girdle weakness, he referred to the disorder as
“proximal myotonic myopathy” (PROMM). A broader
phenotype was described as “proximal myotonic dys-
trophy” in 1997 (Udd et al. 1997). Subsequently, we
reported a large Minnesota kindred with a second form
of myotonic dystrophy (DM2) that closely mimics the
phenotype of adult-onset DM1, and we localized the
disease gene to a 10-cM region on chromosome 3q
(Ranum et al. 1998; Day et al. 1999). Ricker and col-
leagues then reported that the gene for PROMM in
many families also mapped to the DM2 locus (Ricker
et al. 1999). The International Myotonic Dystrophy
Consortium (IDMC 2000) and the Online Mendelian
Inheritance in Man (OMIM) database updated the clin-
ical and scientiﬁc nomenclature so that the chromosome
19 locus is now referred to as “myotonic dystrophy type
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Table 1
Clinical Features of the Myotonic Dystrophies
FEATURE
FINDING FORa
DM1 DM2
Myotonia  
Facial weakness  
Proximal weakness  
Distal weakness  
Sternocleidomastoid atrophy  
Iridescent cataracts  
Cardiac arrhythmias  
Testicular failure  
Hyperinsulinemia  
Hypogammaglobulinemia  
Elevated creatine kinase  
Retardation/congenital abnormalities  
a  p present;  p absent.
1” (DM1) and the locus on chromosome 3 to which
DM2 and many PROMM families map is the DM2
locus. The diseases are collectively referred to as “the
myotonic dystrophies” (DM), and each individual ge-
netic disorder is referred to by the same name as the
locus name (DM1, DM2), whereas “PROMM” can be
used to describe the clinical presentation but is not re-
stricted to any speciﬁc genetic cause or locus.
Clinical Features
Muscle Dysfunction
The multisystemic nature of DM results in varied
symptoms in affected individuals (table 1), although al-
most all affected individuals have clinically identiﬁable
muscle involvement at the time of diagnosis. Muscle dys-
function is the most common presenting complaint in
both DM1 and DM2 (Moxley 1996; Day et al. 1999,
2003; Ricker 1999; Thornton 1999; Harper 2001), with
symptomatic weakness, pain and myotonia. Myotonia
is involuntary muscle contraction and delayed relaxation
due to muscle hyperexcitability.
There are similarities and differences in the muscle
features of DM1 and DM2. Both diseases result in early
clinically detectable weakness of neck ﬂexors and lateral
deep ﬁnger ﬂexors (Moxley 1996; Day et al. 1999; Ma-
thieu et al. 1999; Ricker 1999; Thornton 1999; Harper
2001; Day et al. 2003), although initial symptoms in
DM2 often involve proximal lower extremity muscu-
lature, whereas DM1 is more apt to be associated with
severe muscle atrophy and symptomatic ﬁnger ﬂexor
weakness. DM2 is not associated with severely atrophic
facial and forearm muscles. Electrical myotonia is de-
tectable by electromyography in almost all individuals
with DM1 or DM2; although clinical symptoms of my-
otonia are not typically severe in either disease, patients
with DM1 are often more symptomatic than those with
DM2.
The histological features of DM muscle are distinct,
though not pathognomonic, with dystrophic features ac-
companied by atrophic ﬁbers, scattered severely atrophic
ﬁbers with pyknotic myonuclei, and a marked prolif-
eration of ﬁbers with central nuclei. There is one report
of differences in ﬁber-type involvement in the two dis-
eases, with more type 1 involvement in DM1 and more
type 2 involvement in DM2 (Vihola et al. 2003).
Multisystemic Features
DM1 and DM2 have similar disease-speciﬁc effects
on the eye, heart, and endocrine systems. Ocular in-
volvement results in almost all adults with DM1 or DM2
having posterior subcapsular cataracts, with distinctive
red and green iridescent opacities on slitlamp exami-
nation. Some adults are unaffected by these cataracts,
but other subjects with DM1 or DM2 may require lens
removal as early as the 2nd decade of life (Harper 2001;
Day et al. 2003). Cardiac involvement leads to conduc-
tion defects, arrhythmias, and sudden death in both
DM1 and DM2 (Nguyen et al. 1988; Colleran et al.
1997; Merino et al. 1998; Philips et al. 1998; Day et al.
2003) but does not correlate with severity of skeletal
muscle involvement or repeat length (Lazarus et al.
1999). Endocrine abnormalities in both DM1 and DM2
result in hyperinsulinemia, hyperglycemia, and insulin
insensitivity, with type 2 diabetes occurring in each dis-
order (Harper 2001; Day et al. 2003). Testicular failure
is also common in both disorders, with associated hy-
potestosteronism, elevated follicle-stimulating hormone
(FSH) levels, and oligospermia. Other serological ab-
normalities in both disorders include reduced levels of
immunoglobulin G and M (Harper 2001; Day et al.
2003).
Congenital Myotonic Dystrophy
A primary difference between DM1 and DM2 is that
DM1 can result in a severe congenital form that has not
been reported for DM2. The congenital form of DM1
involves marked developmental abnormalities that can
be present to a lesser degree in patients with DM1 who
become symptomatic during adulthood; the hallmark
developmental features, including craniofacial skeletal
abnormalities, characteristic dysmorphic features, and
mental retardation, have not been reported in DM2.
CNS Involvement
CNS involvement in DM1 involves both (1) devel-
opmental abnormalities with retardation and (2) degen-
erative changes, exempliﬁed by abnormal white matter
changes on MRI scanning, memory deﬁcits, and per-
sonality abnormalities (Rubinsztein et al. 1997; Bun-
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gener et al. 1998; Delaporte 1998; Ogata et al. 1998;
Ono et al. 1998; Wilson et al. 1999). The CNS effects
of DM2 mirror the degenerative changes of DM1, in-
cluding the MRI abnormalities (Hund et al. 1997), but
developmental abnormalities and retardation are not
recognized features of DM2 (Day et al. 2003).
DM1 (CTG)n Repeat Expansion and Instability
In 1992, the chromosome 19 form of DM was shown
to be caused by an expanded CTG repeat located in the
3′ UTR of the myotonia-dystrophica protein kinase
(DMPK [MIM 605377]) gene (Brook et al. 1992; Bux-
ton et al. 1992; Fu et al. 1992; Harley et al. 1992; Ma-
hadevan et al. 1992) and the promoter region of the
immediately adjacent homeodomain gene SIX5 (MIM
600963) (Boucher et al. 1995). DM1 was the ﬁrst au-
tosomal dominant disease found to be caused by an un-
translated trinucleotide repeat expansion, in which the
mutation is transcribed into RNA but not translated into
protein. The CTG expansion in DM1 can vary from 50
to 14,000 repeats in affected individuals. Both intergen-
erational and somatic instability are observed with in-
creases in repeat size on the order of ∼50–80 repeats per
year (Monckton et al. 1995; Martorell et al. 1998). For
DM1, there are reasonably good correlations of repeat
size and age at onset for CTGs !400 repeats (Hamshere
et al. 1999).
The DM1 CTG Expansion: Proposed Mechanisms of
Pathogenesis
Haploinsufﬁciency of DMPK
Because most dominant disorders are caused by the
expression of an abnormal protein with an altered func-
tion, it has not been clear how the multisystemic clinical
features of dominantly inherited DM1 could be caused
by a trinucleotide repeat that did not affect the protein
coding portion of a gene (Tapscott 2000). Initially, the
location of the mutation at the 3′ end of a kinase gene
suggested that alterations in DMPK expression might
cause the multisystemic clinical features of the disease.
Most of the early expression studies were consistentwith
this hypothesis, indicating that DMPK mRNA and pro-
tein levels were reduced in patient muscle and cell culture
(Fu et al. 1992; Hoffmann-Radvanyi et al. 1993; Novelli
et al. 1993). However, DMPK knockout mice generated
to test this hypothesis did not have the typical multis-
ystemic features of the disease. Initial reports of these
mice showed only a very mild, late-onset myopathy that
is not typical of DM1 (Jansen et al. 1996; Reddy et al.
1996). More recently, both hemizygous and homozy-
gous DMPK knockout mice have been reported to have
cardiac conduction abnormalities. When considered to-
gether, these results suggested that DMPK may contrib-
ute to the cardiac features of DM1, but haploinsufﬁ-
ciency of DMPK does not cause the multisystemic
clinical features of DM1. The fact that there are no
reported cases of DM1 caused by point mutations in
the DMPK gene further suggests that the multisystemic
features of DM1 are not caused simply by DMPK
haploinsufﬁciency.
Haploinsufﬁciency of SIX5 and Neighboring Genes
A second proposed mechanism is that the expanded
repeat affects the expression of multiple genes in the
region. Support for this hypothesis comes from the ob-
servation that the CTG expansion is a strong nucleo-
some-binding site that could potentially alter chromatin
structure and have regional effects on the expression of
multiple genes (Wang et al. 1994; Otten and Tapscott
1995). The expansion overlaps not only the 3′ end of
DMPK, but the 5′ promoter region of the neighboring
gene SIX5. SIX5 has a strong resemblance to the fruit
ﬂy gene sine oculis (needed for eye development) and to
a family of mouse genes that regulate distal limb muscle
development. Because cataracts and distal muscle wast-
ing are common in DM1, haploinsufﬁciency of SIX5was
suggested as a possible contributor to DM1 pathogenesis
(Shaw et al. 1993; Boucher et al. 1995; Jansen et al.
1995). In addition to DMPK and SIX5, other neigh-
boring genes suggested to be involved in aspects of DM1
pathogenesis included theDMWD gene immediately up-
stream of DMPK, which is expressed in the testis and
is proposed to play a role in male infertility, and FCGRT
(MIM 601437), an IgG receptor gene located 4Mb from
the CTG expansion, was proposed to underlie the low
IgG levels in DM (Junghans et al. 2001). In this model,
the multisystemic features of DM1 would be explained
by haploinsufﬁciency of a number of neighboring genes,
with expression level—and, hence, disease severity—de-
pendent on repeat length.
Expression studies have focused on examining the
transcript levels of DMPK, DMWD, and SIX5 in both
individuals with DM1 and normal individuals. In the
case of DMPK, an equal amount of unprocessed tran-
scripts are produced from both the normal and the mu-
tant DMPK genes (Krahe et al. 1995), indicating that
there is no interference withDMPK transcription caused
by the CTG expansion. Studies involving SIX5 and
DMWD have given conﬂicting results. Thornton and
colleagues (1997) used an allele-speciﬁc RT-PCR assay
and found that the expression of the CTG repeat ex-
pansion-linked SIX5 allele was reduced—in some cases
approaching inactivation—compared with the other
SIX5 allele. This reduction was seen with pre-mRNA,
as well as with processed mRNA. Klesert and colleagues
(1997) demonstrated that a DNase I hypersensitive site,
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shown by Otten and Tapscott (1995) to be eliminated
by the CTG repeat expansion, contains an enhancer se-
quence for the SIX5 gene but not for the DMPK gene,
and that expansion of the CTG reduces the transcription
of the SIX5 allele located cis to the expansion. Data
generated by Hamshere and colleagues (1997), indicated
that the cytoplasmic expression of both SIX5 and
DMWD was the same in both normal and DM1 cells.
The most compelling support for the involvement of
neighboring genes in DM pathogenesis came from the
fact that Six5 knockout mice develop cataracts (Klesert
et al. 2000; Sarkar et al. 2000). Although cataracts are
one of the clinical features of DM, the cataracts in the
Six5 knockouts do not have the distinctive iridescent
opacities or the posterior location that is associated with
myotonic dystrophy in humans.
RNA Pathogenesis
A third hypothesized mechanism is that the enlarged
CUG-containing transcripts that accumulate as foci in
the nuclei of both cultured cells and biopsied tissue (Ta-
neja et al. 1995; Davis et al. 1997) exert a trans-dom-
inant effect that disrupts splicing and possibly other cel-
lular functions (Timchenko et al. 1996a; Philips et al.
1998; Lu et al. 1999; Miller et al. 2000; Savkur et al.
2001). Strong experimental support for the involvement
of an RNA mechanism in skeletal muscle pathology
came from a mouse model developed by Mankodi and
colleagues (2000). Initial attempts to develop animal
models to study the effects of the expression of elongated
CUG expansions in transgenic mice were hampered by
infertility of the mice, which prevented successful breed-
ing (Monckton et al. 1998). In 2000, Mankodi and col-
leagues avoided this problem by developing a mouse
model in which the CTG expansion was inserted into
the 3′ end of the human skeletal actin gene, a gene not
thought to be involved in DM1 but the expression of
which is limited to skeletal muscle (Mankodi et al.
2000). This mouse model, which expressed an mRNA
with a CUG repeat tract of ∼250 repeats was the ﬁrst
to develop the myotonia and the myopathic features
characteristic of DM1 (Mankodi et al. 2000). However,
because the expression of the CUG-containing tran-
scripts in this model was limited to skeletal muscle, the
role of the CUG expansion in the multisystemic features
of DM was not addressed.
Additive Model of DM1 Pathogenesis
Subsequently, an additive model was proposed in
which each of the above mechanisms contributes to
DM1 pathogenesis (Groenen and Wieringa 1998; Tap-
scott 2000; Filippova et al. 2001; Larkin and Fardaei
2001), with some aspects of the disease caused by hap-
loinsufﬁciency of DMPK, SIX5, and other neighboring
genes and other clinical features resulting from effects
of the CUG expansion in RNA. An inconsistency with
the additive model of DM1 pathogenesis was that the
genetic locus for DM2 maps to a different chromosome,
with no known conservation between the two chro-
mosomal regions (Ranum et al. 1998).
DM2 Caused by CCTG Expansion in Intron 1 of
ZNF9
Given the confusion in understanding the molecular
pathogenesis of DM1, the identiﬁcation of a second hu-
man mutation that causes the multisystemic effects of
DM and a determination of what is common to these
diseases at the molecular level, provided an independent
means of evaluating the pathogenic pathway(s) of DM.
In 2001, we demonstrated that DM2 is also caused by
a transcribed but untranslated repeat expansion—but
this time a CCTG repeat expansion located in intron 1
of the zinc ﬁnger protein 9 (ZNF9) gene (MIM 116955).
Although DM2 is generally a milder disease than DM1,
the DM2 CCTG expansions can be much larger than
DM1 CTG expansions, with alleles ranging in size from
∼75 to 11,000 CCTG repeats (mean ∼5,000 CCTGs).
The smallest pathogenic size is not yet clear, because
somatic instability has resulted in individuals with un-
common shorter expansions also having larger allele
sizes in lymphocyte DNA (Liquori et al. 2001).
The DM2 CCTG expansion mutations show both
somatic and intergenerational instability. In peripheral
blood samples, the degree of somatic instability is so
extreme that one in ﬁve DM2 expansions is not de-
tectable by Southern analysis because of size hetero-
geneity. This causes a diagnostic challenge for DM2 not
previously encountered with DM1 or any of the other
reported microsatellite expansion disorders (Liquori et
al. 2001; Day et al. 2003). Although anticipation has
been reported in DM2/PROMM families, on the basis
of clinical criteria (Schneider et al. 2000; Day et al.
2003), the expected trend of longer repeat expansions
in patients with earlier ages at onset was not observed
(Schneider et al. 2000; Day et al. 2003), with the so-
matic instability of the repeat clearly complicating this
analysis (Liquori et al. 2001).
The DM2 repeat tract contains the complex repeat
motif (TG)n (TCTG)n (CCTG)n. The CCTG portion of
the repeat tract is interrupted on normal alleles, but as
in other expansion disorders these interruptions are lost
on affected alleles. Haplotype analysis of 228 control
chromosomes identiﬁed a potential premutation allele
with an uninterrupted (CCTG)20 on a haplotype that
was identical to the most common affected haplotype.
Similar to some of the other microsatellite expansion
disorders (Chung et al. 1993; Kunst and Warren 1994;
Pulst et al. 1996; Gunter et al. 1998), the loss of se-
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Figure 1 RNA in situ hybridization of the expansion. A, In situ hybridization of CAGG probe to DM2 muscle. B, In situ hybridization
of CAGG probe to normal muscle. C, In situ hybridization of CAG probe to DM1 muscle. The scale bar is 5 mM. (Reprinted from Science
293:864–867.)
quence interruptions within the CCTG portion of the
DM2 repeat tract may predispose alleles to further ex-
pansion (Liquori et al. 2003).
Our 2001 discovery of the DM2 CCTG expansion
allowed for further analysis of the genetic heterogeneity
of DM. It now appears that most if not all families with
dominant multisystemic myotonic disorders have either
DM1 orDM2 expansions, with no convincing examples
that would suggest the existence of a third mutation
that causes a similar disorder—that is, DM3 (Day et al.
2003). Families previously reported to have a form of
DM or PROMM not linked to either the DM1 or DM2
loci were subsequently shown to carry the DM2 CCTG
expansion (Day et al. 2003). Linkage disequilibrium
and haplotype analysis suggest that single founder mu-
tations led to the CTG and CCTG expansions respon-
sible for both DM1 and DM2 (Imbert et al. 1993; Ne-
ville et al. 1994; Chakraborty et al. 1996; Bachinski et
al. 2003; Liquori et al. 2003).
DM2: Evidence that RNA Pathogenesis Causes
Multisystemic Clinical Features
The location of the CCTG expansion within intron 1 of
ZNF9 is similar to the DM1 CTG expansion, in that
both repeats are transcribed into RNA but do not alter
the protein coding portion of a gene (Liquori et al.
2001). The normal function of ZNF9 as a nucleic acid–
binding protein (Pellizzoni et al. 1997, 1998; Shimizu et
al. 2003) appears unrelated to any of the proteins en-
coded in the DM1 region of chromosome 19. Similarly,
genes in the DM2 region (KIAA1160, Rab 11B, gly-
coprotein IX, FLJ11631, and FLJ12057) bear no ob-
vious relationship to genes near the DM1 locus (DMPK,
SIX5, DMWD, and FCGRT). Even if the DM2 expan-
sion alters the regulation of ZNF9 and other genes in
the DM2 region, it would be unlikely that alterations in
the regulation of different sets of proteins at the DM1
and DM2 loci would result in diseases with such strik-
ingly similar multisystemic features.
The ﬁrst suggestion that CUG-containing transcripts
were involved in DM1 pathogenesis came from FISH
experiments demonstrating that CUG-containing nu-
clear RNA foci accumulate in DM1 cells (Taneja et al.
1995). Evidence that DM1 and DM2 share a common
pathogenic RNA mechanism comes from experiments
showing that similar CCUG-containing RNA foci are
found in DM2 muscle (ﬁg. 1) (Liquori et al. 2001).
These results demonstrate that the CCTG expansion is
expressed at the RNA level, but additional experiments
are needed to determine if the RNA foci contain the
entire unprocessed ZNF9 transcript or if the transcript
is normally processed but the intron or the repeat tract
alone resists degradation forming the RNA foci. Ad-
ditional evidence that RNA foci containing the DM1
and DM2 repeat motifs behave in a similar manner is
that several forms of the RNA-binding protein muscle-
blind (MBNL, MBLL, and MBXL) colocalize to the
repeat-containing foci in both diseases (Mankodi et al.
2001; Fardaei et al. 2002).
Although the additive model of DM1 suggested that
CUG repeats in RNA cause the myotonia and muscular
dystrophy of DM1, the causes of other DM features—
including cardiac conduction defects and cataracts—
had been ascribed to haploinsufﬁciency of genes in the
DM1 region. The clinical and molecular parallels be-
tween DM1 and DM2 suggest a simpler model of DM
pathogenesis (ﬁgs. 2 and 3), in which the clinical fea-
tures common to both diseases—including myotonia,
muscular dystrophy, cataracts, cardiac arrythmias, in-
sulin insensitivity and diabetes, hypogammaglobuline-
mia, and testicular failure—are caused by the patho-
genic effects of RNA containing the CUG and CCUG
expansions (Day et al. 1999; Liquori et al. 2001)
Although DM1 and DM2 phenotypes are strikingly
similar, they are not identical. DM2 does not show a
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Figure 2 RNA model of DM pathogenesis. The unusual and rare multisystemic clinical parallels between DM1 and DM2 suggest a similar
pathogenic mechanism. The discovery that DM2 mapped to chromosome 3 and not the DM1 region of chromosome 19 make it unlikely that
regional effects of gene expression play a major role in causing the common clinical features of the disease because regional disregulation would
affect different sets of genes. The discovery that a CCTG repeat expansion located on chromosome 3 which is expressed at the RNA but not
the protein level causes DM2, and the observation that both CUG and CCUG repeat–containing foci accumulate in affected muscle nuclei
suggests that a gain-of-function RNA mechanism underlies the clinical features common to both diseases. Speciﬁc changes in pre-mRNA splicing
have been that have been associated with several genes, including the insulin receptor, the chloride channel, and cardiac troponin T, are correlated
with insulin resistance, myotonia, and possibly cardiac abnormalities. (Adapted from Curr Opin Genet Dev 12:266–271.)
Figure 3 Schematic diagram of steps involved in RNA gain-of-
function mechanism. CTG and CCTG expansions at the DM1 or DM2
loci result in the accumulation of CUG or CCUG repeat–containing
transcripts as nuclear RNA foci. RNA-binding proteins, including
CUG-BP and the muscleblind family of proteins bind to or are dis-
regulated by the repeat-containing RNA transcripts resulting in speciﬁc
trans-alterations in pre-mRNA splicing.
congenital form or mental retardation that can occur
in DM1 (Liquori et al. 2001). Downstream differences
of the CUG vs. CCUG expansions could be responsible
for the clinical distinctions between these diseases as
could differences in temporal or spatial levels of tran-
scripts containing the expanded repeats. A possible
mechanism for congenital DM1 has been suggested by
Fillipova and colleagues, who showed that methylation
at the DM1 locus in congenital cases can increase ex-
pression of DMPK, resulting in higher levels of CUG-
containing transcripts and the more severe congenital
phenotype (Filippova et al. 2001). Alternatively, the dif-
ferences between DM1 and DM2 could involve locus-
speciﬁc genes such as DMPK, SIX5, or DMWD for
DM1, and ZNF9 for DM2.
Dominant RNA Mechanism: Speciﬁc Targets of
Abnormal Pre-mRNA Splicing
Evidence that a gain-of-function alteration at the RNA
level plays a role in DM1 pathogenesis includes (i) the
observation that an expanded repeat in the 3′ UTR of
DMPK mRNA inhibits myoblast differentiation (Amack
et al. 1999); (ii) transgenic models in which 1250 CTG
repeats expressed at the RNA level cause myotonia and
muscular dystrophy (Mankodi et al. 2000; Seznec et al.
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2001); (iii) CUG- and CCUG-containing transcripts that
accumulate as RNA foci alter the regulation or locali-
zation of CUG-binding proteins, including CUG-BP
(Timchenko et al. 1996a) and three different forms of
muscleblind (Miller et al. 2000; Fardaei et al. 2002); (iv)
altered CUG- and CCUG-induced splicing changes that
are directly related to phenotypic features of DM. A
recent report using cell-culture models suggests that
CUG RNA expansions bind and sequester transcription
factors in DM1 and may disrupt gene regulation in-
cluding the chloride channel ClC-1 (Ebralidze et al.
2004), but the role of altered gene transcription in
DM pathogenesis is not clear and will need further
investigation.
The currently identiﬁed splicing alterations are de-
scribed in further detail below.
Cardiac Troponin T (cTNT)
Initial efforts to understand how the DM1 CUG ex-
pansion expressed at the RNA level could mediate a
trans-dominant effect focused on the identiﬁcation of
RNA-binding proteins that could bind to CUG repeat
motifs. The ﬁrst of these proteins to be isolated and
described in detail was CUG-binding protein (CUG-BP)
(Timchenko et al. 1996a, 1996b). In a landmark dis-
covery in 1998, Phillips and colleagues (1998) reported
that CUG-BP, a conserved heterogeneous nuclear ribo-
nucleoprotein, could mediate a trans-dominant effect of
excess CUG repeat–containing RNA by disregulating the
alternative splicing of cardiac troponin T (cTNT). CUG-
BP was shown to bind to intronic CUG repeat sequences
in human cardiac troponin T (cTNT) pre-mRNA, which
are normally used as splicing signals. The presence of
excess numbers of CUG repeats in transfection studies
and in DM1 cardiac and skeletal muscle cultures cause
the preferential inclusion of exon 5, which is a splice
form produced during the early development of heart
and skeletal muscle but not in adult heart. This typical
splicing pattern of cTNT is disrupted in DM1 striated
muscle and in transfected cells expressing either CUG-
BP protein or elongated CUG-containing transcripts.
This was the ﬁrst demonstrated splicing target of CUG-
BP and the ﬁrst demonstration that the presence of elon-
gated CUG repeat motifs lead to trans alterations in gene
splicing (Philips et al. 1998).
Insulin Receptor (IR)
A classic clinical feature in both DM1 and DM2 pa-
tients is insulin resistance; the reduced insulin response
in skeletal muscle predisposes DM patients to diabetes.
Savkur et al. (2001) demonstrated that alternative splic-
ing of the insulin receptor (IR) pre-mRNA is aberrantly
regulated in DM1 skeletal muscle tissue, resulting in pre-
dominant expression of the insulin insensitive nonmuscle
splice form lacking exon 11. Steady state levels of CUG-
BP are increased in skeletal muscle of DM1 patients and
disregulation of CUG-BP is thought to mediate an IR
alternative splicing switch by the binding to an intronic
element upstream of the alternatively spliced exon 11.
These results support a model in which increased ex-
pression of a splicing regulator contributes to insulin
resistance in DM1 by affecting IR alternative splicing
(Savkur et al. 2001).
Muscle-Speciﬁc Chloride Channel
A classic feature of both DM1 and DM2 is myotonia,
in which voluntary muscle contraction is followed by
involuntary repetitive ﬁring of action potentials that de-
lay a patient’s ability to relax muscle (Harper 2001).
Using skeletal muscle from a transgenic mouse model of
DM1, Mankodi and colleagues (2000, 2002) showed
that expression of expanded CUG repeats in skeletal
muscle reduces the transmembrane chloride conductance
to levels consistent with those expected to cause myo-
tonia. Additional studies determined that aberrant splic-
ing of Clc-1, the main chloride channel in muscle, re-
sulting in loss of Clc-1 protein from the surface mem-
brane (Mankodi et al. 2002). Similar splicing alterations
were observed in skeletal muscle from both DM1 and
DM2 patients (Charlet et al. 2002;Mankodi et al. 2002).
Charlet and colleagues (2002) demonstrated that CUG-
BP, which is elevated in DM1 skeletal muscle, binds to
the ClC-1 pre-mRNA, and overexpression of CUG-BP
in transfected cells reproduces the aberrant pattern of
ClC-1 splicing. Both groups propose that disruptions in
alternative splicing regulation of ClC-1 causes a chan-
nelopathy and membrane hyperexcitability, leading to
the classic DM feature of myotonia (Charlet et al. 2002;
Mankodi et al. 2002).
Tau and Myotubularin
Splicing alterations in the microtubule-associated tau
pre-mRNA have been observed in CNS tissue from pa-
tients with DM1 (Sergeant et al. 2001) and in a murine
model described by Seznec and colleagues (2001), which
may underlie various CNS alterations in both diseases.
Also, muscle-speciﬁc changes in alternative splicing of
the myotubularin-related 1 (MTMR1) gene are observed
in congenital DM1 muscle cells in culture and in skele-
tal muscle samples from patients with congenital-onset
DM1. These results suggest that MTMR1 plays a role
in muscle formation and represents a novel target for
abnormal mRNA splicing in myotonic dystrophy that
may be responsible for the profound muscle atrophy of
congenital DM1 (Buj-Bello et al. 2002).
Are RNA Foci Pathogenic or Protective?
Neurodegenerative diseases, such as Alzheimer disease
and those caused by polyglutamine expansions, result in
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protein aggregates or plaques and tangles that accu-
mulate in affected tissues and have led investigators to
debate their role in disease pathogenesis (Hsiao et al.
1995; Klement et al. 1998). Similar discussions in the
DM ﬁeld revolve around the role of RNA foci in disease
pathogenesis. CUG-BP, the ﬁrst RNA-binding protein
with a demonstrated pathogenic effect, has been shown
to bind to single-stranded CUG repeats. In contrast with
the muscleblind family of proteins, CUG-BP does not
colocalize with the nuclear RNA foci in DM1 and DM2.
Although it appeared possible that both groups of pro-
teins play a role in the pathogenic effects of DM, co-
localization of a protein to the ribonuclear inclusions
did not appear to be necessary to cause a pathogenic
effect.
Direct evidence supporting the hypothesis that se-
questration of muscleblind in CUG and CCUG con-
taining RNA foci plays a central role in disease path-
ogenesis comes from a recently developed muscleblind
knockout model of myotonic dystrophy. Kanadia and
colleagues showed that disruption of the mouse Mbnl1
gene leads to muscle, eye, and RNA-splicing abnor-
malities that are characteristic of DM1 and DM2 in
humans (Kanadia et al. 2003).
Data now indicate that overexpression of CUG-BP
and depletion of Mbnl1 both can cause speciﬁc alter-
native-splicing changes. Previous studies have reported
that expression of elongated CUG-containing tran-
scripts result in increased levels of CUG-BP through an
unknown mechanism. In contrast, the sequestration of
Mbnl1 in CUG and CCUGRNA foci has been proposed
as a mechanism that results in Mbnl1 depletion. It now
appears that both of these proteins play a role in af-
fecting alternative splicing and that, in the case of ClC1,
changes through antagonistic effects in which CUG-BP
promotes the inclusion of exons that are normally fa-
vored during fetal development, whereas the normal
function of Mbnl1 is to favor splice forms expressed in
adults. These data predict that overexpression of CUG-
BP or depletion of Mbnl1 would both result in the splic-
ing alterations and that changes in the regulation of
either these proteins can cause downstream splicing
changes that have now been shown to be characteristic
of the myotonic dystrophies.
Other Noncoding Disorders
Although the striking clinical and molecular parallels
between DM1 and DM2 demonstrate that RNA path-
ogenesis plays a much broader role in the multisystemic
features of myotonic dystrophy than previously sus-
pected, noncoding microsatellite expansions for SCA8
(Koob et al. 1999) and SCA10 (Matsuura et al. 2000)
were identiﬁed before the DM2 expansion. The patho-
genic mechanism of the DM1 and DM2 expansions are
evident only because they cause such a distinctive phe-
notype. Molecular parallels between the SCA8 CUG re-
peat and the DM1 and DM2 repeats suggest the pos-
sibility that the known toxic properties of transcripts
with elongated CUGs underlie the cerebellar degenera-
tion in SCA8 (Ranum and Day 2002). Although, in
SCA10, it is possible that the enormous ATTCT expan-
sion in an intron of a gene may cause disease through
haploinsufﬁciency, the dominant inheritance pattern and
the fact the expression of the SCA10 transcript does not
appear to be reduced in affected individuals (Matsuura
et al. 2000) make this potential mechanism less likely.
Parallels between SCA10 and the RNA mechanism in-
volved in DM1, DM2, and possibly SCA8 suggest a
gain-of-function mechanism at the RNA level could be
involved. Unlike SCA8, the gene that harbors the mu-
tation for SCA10 is ubiquitously expressed, indicating
that, if a toxic RNA mechanism is involved, secondary
proteins that interact with the AUUCU repeat motif may
confer organ-speciﬁc pathogenicity (Matsuura et al.
2000). FMR premutation alleles that have recently been
reported to be associated with a tremor-ataxia syndrome
may involve a similar RNA mechanism (Brunberg et al.
2002; Aziz et al. 2003; Jacquemont et al. 2003).
Conclusions
The clinical and molecular parallels of DM1 and DM2
demonstrate the multisystemic effects of CUG and
CCUG expansions. A detailed description of trans-dom-
inant splicing alterations of genes relevant to the DM
phenotype is emerging, providing a convincing model of
how these RNA expansions cause myotonic dystrophy.
In other microsatellite-expansion diseases, including
SCA8 and SCA10, transcribed noncoding expansions
cause very different CNS phenotypes, suggesting that
dominant RNA mechanisms may be a general cause of
disease.
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